# Thymulin: The Zinc-Bound Thymic Nonapeptide, Read Study by Study > Thymulin is a zinc-dependent thymic nonapeptide hormone, biologically active only when bound to zinc 1:1. An editorial digest of the immune, anti-inflammatory, and neuroendocrine research, cited to source. Nine amino acids, one zinc ion, and a research record that runs from a 1982 conformation discovery to inhaled gene therapy in mice. This is a reading list of that literature, with every quantitative claim cited. ## The short version Thymulin (a small hormone made by the thymus, the immune-training gland behind the breastbone) is a nonapeptide — a chain of nine amino-acid building blocks — and it has one defining trick: it only switches on when a single zinc atom is attached. The zinc-free version is inert. Attach one zinc, and the molecule folds into the shape that drives T cells (the immune system's trained defender cells) to mature. In animal and lab studies it also calms inflammation. It is a research peptide, not an approved medicine, and it is **not** the same thing as thymosin alpha-1 or thymosin beta-4. ## Thymulin Peptide: A Zinc-Dependent Thymic Nonapeptide Thymulin is a linear nonapeptide — a chain of nine amino-acid building blocks — with the sequence pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn and the molecular formula C33H54N12O15 (molecular weight roughly 858.86 Da) [1]. It is produced exclusively by thymic epithelial cells (the lining cells of the thymus that build the hormone), and it circulates from birth, peaks in childhood, and falls with age and with zinc deficiency [4]. That developmental arc matters: thymulin is not a constant background signal but a hormone whose supply rises and fades across a lifetime, which is part of why it became a candidate molecule in immune-aging research. The peptide carries one decisive condition for activity. In the original 1982 work that named it, treating the parent molecule — then called serum thymic factor, or FTS — with a metal-stripping chelator abolished its activity in a cell bioassay; adding zinc back restored it, with an optimal one-zinc-to-one-peptide ratio [1]. The authors proposed the name "thymulin" specifically for the zinc-bound, active form. That binary — inert without zinc, active with it — is the single most important fact about the molecule, and the [zinc dependence of thymulin](/zinc-dependence) is its own page here. Later work resolved the zinc-bound form's specific three-dimensional shape by NMR, confirming that zinc is structural rather than incidental [2]. This is also where most consumer writing goes wrong. Thymulin is chemically and pharmacologically distinct from thymosin alpha-1 and from thymalin, a bovine thymic complex it is frequently confused with [4]. It is likewise not thymosin beta-4. Their sequences differ, their pharmacology differs, and their research does not transfer between them. This site keeps them apart on purpose, because conflating them is the fastest way to attribute a finding to the wrong molecule. ## What the literature has actually demonstrated The thymulin record is preclinical-dominant, dated in places, and unusually specific. A few findings carry it. In LPS-treated mice — a standard bacterial-toxin model of acute inflammation — thymulin given daily for two weeks before the challenge lowered plasma pro-inflammatory cytokines and inducible heat-shock proteins, and modulated NF-kB (a master switch that turns inflammation genes on) and SAPK/JNK signaling [6]. A separate model found thymulin prevented the overproduction of pro-inflammatory cytokines and the heat-shock protein Hsp70 [9]. Injected directly into rat brain ventricles, thymulin reduced NF-kB activation in the hippocampus [10]. That NF-kB thread is the spine of the [thymulin anti-inflammatory effects](/anti-inflammatory-effects) page. The immune work is older and foundational. Thymulin drives T-lymphocyte maturation — the process by which T cells, the immune system's trained defender cells, develop into functional subsets — and modulates that subset balance, with activity that tracks zinc status [12]. In humans with mild zinc deficiency, serum thymulin activity fell despite normal plasma zinc and was corrected by zinc repletion [3]. The reach extends past immunity, too: thymulin behaves as a hypophysiotropic peptide, signaling the pituitary within a bidirectional thymus-neuroendocrine axis [4]. And one 2020 result stands out: a single inhaled dose of thymulin-expressing plasmids, delivered in mucus-penetrating nanoparticles after experimental asthma was fully established in mice, normalized the key lung pathologies at 20 days [7]. A 2010 review reads thymulin's immunomodulatory role across experimental lung disease as consistently protective [15]. These are findings in named species and models — not demonstrated treatments in people. The [thymulin research findings](/research) page lays them out in full, with the honest gaps marked rather than filled. ## What the Research Shows: Thymulin Peptide in Preclinical Models Read as a body of work, the thymulin peptide benefits reported in the literature cluster in three domains, all preclinical or in vitro. **Immune.** Synthetic thymulin induced T-cell markers on human marrow precursors in vitro, and the peptide promotes T-lymphocyte differentiation and subset balance [12]. In a mouse model of severe experimental autoimmune encephalomyelitis — a multiple-sclerosis model — thymulin modulated the inflammatory response and reduced disease severity [4]. **Anti-inflammatory.** Beyond the LPS and NF-kB work above, prolonged thymulin treatment in streptozotocin-diabetic mice lowered blood glucose and pro-inflammatory cytokines (TNF-alpha, IL-5, IL-17, IFN-gamma) while modulating NF-kB/JNK activity [8], and FTS pretreatment protected pancreatic acinar cells from LPS injury via Bcl-2 upregulation, at 50 micrograms per mouse [11]. **Neuroendocrine.** Thymulin acts as a hypophysiotropic peptide — one that signals the pituitary — within a bidirectional thymus-neuroendocrine axis, for example stimulating pituitary ACTH release in vitro [4]. None of this is a human benefit. It is what specific studies measured in specific models. ## How Thymulin Differs from Thymosin Alpha-1 This section exists because the confusion is constant. Thymulin is a zinc-dependent nonapeptide — nine residues — active only when one zinc ion is bound [1]. Thymosin alpha-1 is a different, longer thymic peptide with its own pharmacology. They are not interchangeable, and thymulin's data should never be described using thymosin alpha-1's name or findings [4]. The same caution applies to thymosin beta-4 and to thymalin, the bovine thymic polypeptide complex thymulin is often confused with in consumer sources [4]. Different molecules, different evidence. When you read a claim about "thymic peptides," check which one the study actually used — and read [how thymulin differs from thymosin alpha-1](/) before assuming the research carries across. Thymulin is not FDA-approved for any use and is handled as a research peptide. It is not a dietary supplement. The honest framing throughout this site is research-context only. ## How to read the rest of this site This digest is organized so the science stays separable from the spin. The [thymulin research findings](/research) page walks the full literature, from the 1982 conformation discovery to the 2020 lung result, with each finding tagged by species and model. The dedicated [thymulin anti-inflammatory effects](/anti-inflammatory-effects) page follows the NF-kB thread — the dealt lens of this reader — across brain, body, and lung. The [zinc dependence of thymulin](/zinc-dependence) page covers the one fact everything else rests on. The [thymulin dosing in studies](/dosage) page reports study doses by species and route only, never as a human protocol. Three commitments run through all of them. Every quantitative claim is cited [1][6][7]. Findings are described in their study species and models, never as treatments or human dosing guidance. And thymulin is kept distinct from the other thymic peptides it is so often confused with. Where the human record is thin, the [thymulin questions answered](/faq) page says so directly rather than papering over the gap. --- A small-press reader for the zinc-bound thymulin literature — printed from the peer-reviewed record, not a clinic, not a counter, not a prescription.